Ozempic vs Mounjaro
Ozempic
GLP-1 receptor agonist for diabetes and weight management with established clinical data.
Patients seeking proven, cost-effective diabetes control with established cardiovascular benefits, or those preferring a more established medication with greater insurance coverage.
VS
M
Mounjaro
Dual GIP/GLP-1 receptor agonist delivering superior weight loss and diabetes control through dual-pathway mechanism.
Patients prioritizing maximum weight loss, optimal diabetes control, or those who haven't achieved goals with single-pathway GLP-1 agents, and those with adequate insurance coverage.
Short Answer
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results. Mounjaro targets two pathways compared to Ozempic's single pathway, making it potentially more effective for weight management.
Our Verdict
Mounjaro demonstrates superior weight loss and diabetes control due to its dual-mechanism approach, making it the better choice for maximum results. However, Ozempic remains established with more clinical history, better availability, and lower cost, making it ideal for those seeking proven efficacy or budget-conscious patients. The choice depends on individual goals, insurance coverage, and medical history.
Ozempic7.5
7.5Mounjaro
Choose Ozempic if
Patients seeking proven, cost-effective diabetes control with established cardiovascular benefits, or those preferring a more established medication with greater insurance coverage.
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
🔹
Drug Class: Mounjaro wins (GIP/GLP-1 receptor agonist (dual agonist) vs GLP-1 receptor agonist)
⚖️
Average Weight Loss: Mounjaro wins (20-22% body weight vs 15-18% body weight)
⚖️
FDA Approval for Weight Loss: Ozempic wins (Approved (Wegovy brand, 2021) vs Approved (Zepbound brand, 2023))
Key Facts & Figures
| Metric | Ozempic | Mounjaro | Diff |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| FDA Approval Year(year) | 2017 | — | — |
| Number of Dose Strengths Available(strengths) | 4 | — | — |
| Typical Weight Loss at Maximum Dose |
Key Differences
Ozempic
Attribute
Mounjaro
GLP-1 receptor agonist
Drug Class
GIP/GLP-1 receptor agonist (dual agonist)🏆
15-18% body weight
Average Weight Loss
20-22% body weight🏆
Approved (Wegovy brand, 2021)🏆
Related Comparisons
W
O
Wegovy vs Ozempic
health
W
O
Wegovy vs Ozempic
products
O
W
Ozempic vs Wegovy
health
T
A
Tylenol vs Advil
health
A
O
Almond Milk vs Oat Milk
health
V
V
Vegan vs Vegetarian
health
K
P
Keto vs Paleo
health
R
W
Running vs Walking
health
Y
P
Yoga vs Pilates
health
F
C
Flu Shot vs COVID Vaccine
health
O
N
Organic Food vs Non-Organic Food
health
T
M
Therapy vs Medication
health
Related Articles
Explore Entities
More Health & Wellness
Last updated: May 23, 2026AI generated
